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Stress-related neuropsychiatric disorders are widespread, debilitating and often treatment-resistant 
illnesses that represent an urgent unmet biomedical problem. Animal models of these disorders 
are widely used to study stress pathogenesis. A more recent and historically less utilized model 
organism, the zebrafish (Danio rerio), is a valuable tool in stress neuroscience research. Utilizing the 
5-week chronic unpredictable stress (CUS) model, here we examined brain transcriptomic profiles and 
complex dynamic behavioral stress responses, as well as neurochemical alterations in adult zebrafish 
and their correction by chronic antidepressant, fluoxetine, treatment. Overall, CUS induced complex 
neurochemical and behavioral alterations in zebrafish, including stable anxiety-like behaviors and 
serotonin metabolism deficits. Chronic fluoxetine (0.1 mg/L for 11 days) rescued most of the observed 
behavioral and neurochemical responses. Finally, whole-genome brain transcriptomic analyses 
revealed altered expression of various CNS genes (partially rescued by chronic fluoxetine), including 
inflammation-, ubiquitin- and arrestin-related genes. Collectively, this supports zebrafish as a valuable 
translational tool to study stress-related pathogenesis, whose anxiety and serotonergic deficits 
parallel rodent and clinical studies, and genomic analyses implicate neuroinflammation, structural 
neuronal remodeling and arrestin/ubiquitin pathways in both stress pathogenesis and its potential 
therapy.
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Stress evokes multiple behavioral and physiological  responses1,2, including neuroendocrine and immune 
 deficits3–7, that may trigger common affective illnesses, such as anxiety, depression and post-traumatic stress 
disorder (PTSD)8–11. Widespread, debilitating and often treatment-resistant, these neuropsychiatric disorders 
represent an urgent unmet biomedical  problem12–14, complicated by their multiple overlapping genetic and 
environmental determinants, and poor understanding of their mechanisms and risk  factors15,16. Animal models, 
especially employing rodents, are widely used to study stress biology and  pathogenesis17–19. Commonly utilizing 
various chronic unpredictable stress (CUS)  protocols20–24, such models typically expose rodents to continuous 
exposure to varying stressors for several  weeks22,24–27, to evoke anxiety- and/or depression-like  states28–30 and 
physiological alterations that resemble those observed  clinically31.
A more recently recognized and historically less utilized model organism, the zebrafish (Danio rerio) is rapidly 
becoming a critical species for translational neuroscience research, complementing rodent  studies32,33. For exam-
ple zebrafish demonstrate high genetic and physiological similarity to  humans34,35, and possess major, evolutionar-
ily conserved neurotransmitter  systems36,37 and shared central nervous system (CNS)  morphology38,39. Zebrafish 
are also widely used in stress  research40–42, often based on various aquatic CUS protocols adapted from rodent 
 models43–47. Here, we utilize a rigorous 5-week CUS protocol, already established in our  laboratory48, to examine 
brain transcriptomic changes and weekly dynamics of behavioral and neurochemical stress responses in adult 
zebrafish (Fig. 1, Table 1), as well as their potential correction by fluoxetine, a common, clinically efficient and 
most prescribed selective serotonin reuptake inhibitor (SSRI) antidepressant. 
Results
The generalized linear models 1 (GZLM1) analyses were used in the present study to compare CUS and con-
trol zebrafish groups in the novel tank test (NTT) across all 5 weeks of stress, revealing significant Wald test effects 
for week, group for distance traveled, as well as the time spent in top, with significant within-week differences 
between control and stressed fish in all five experimental weeks (Table 2, Supplementary Tables S2–S4). There 
were also significant group, week and week × group effects for time spent not moving, where the post-hoc Tukey’s 
test revealed only the significant difference within week group (control vs. stress) for week 2, but not other weeks 
(Table 2, Supplementary Tables S2–S4). We also found significant week and interaction, but not group, effects for 
the number of top entries, as Tukey’s test for week groups revealed significant differences vs. control only at week 
1 (Table 2, Supplementary Tables S2–S4). Finally, significant week, group and interaction effects were found for 
the latency to enter the top, whose post-hoc pairwise week comparisons revealed significant differences from 
controls in weeks 2, 3 and 5 (Table 2, Supplementary Tables S2–S4).
Generalized linear models 2 (GZLM2) analyses of CUS, fluoxetine and control groups at week 5 revealed 
significant NTT group effect for distance travelled, with significant differences between stress vs. both control 
and fluoxetine by post-hoc Tukey’s test (Table 3). There was also significant group effect for time spent in top, 
with significant differences in control vs. stress and vs. fluoxetine (Table 3). Finally, significant group effect was 
found for the latency to enter the top, yielding significant stress vs. control and vs. fluoxetine differences, as 
assessed by the post-hoc Tukey’s test (Table 3).
Applying GZLM1 analyses to the light–dark test (LDT), showed significant group and week × group effects 
for time spent in light. Post-hoc Tukey’s test comparison of the weeks revealed significant differences between 
stress and control groups at weeks 1–3, but not other weeks of CUS (Table 2, Supplementary Tables S2–S4). In 
contrast, there were no significant effects for any predictor studied for the number of light entries (Table 2), and 
no group effects were observed in GZLM2 using the Wald test for the LDT endpoints (Table 3).
Figure 1.  A brief diagram outlining the study experimental design, including the chronic unpredictable stress 
(CUS) protocol and behavioral testing (see Table 1 for details of CUS stressors applied in the present study). 
NTT the novel tank test, LDT the light–dark test, SH shoaling test, ZTI the zebrafish tail immobilization test, 
HPLC high-performance liquid chromatography, RNASeq RNA sequencing.
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In the shoaling test (ST), there was a significant group effect, but not week or interaction, for the average 
inter-fish distance. The distance to the surface showed significant week and week × group, but no group effects 
(Table 2), with groups differing at weeks 1–2, but not other CUS weeks (Supplementary Table S5). GZLM2 analy-
ses also showed significant group effects, with stress vs. control and vs. fluoxetine fish for the average inter-fish 
distance, as assessed by Tukey’s post-hoc testing (Table 3).
Finally, GZLM1 analyses of the zebrafish tail immobilization (ZTI) test data established significant week and 
week × group (but not group) effects for time spent active (Table 2), with no significant GZLM2 effects using 
the Wald test for the ZTI test endpoints (Table 3). There was also a significant week × group interaction for the 
5-hydroxyindoleacetic acid (5-HIAA) content and the 5-HIAA/serotonin ratio, with no week or group effects 
Table 1.  A brief summary of the chronic unpredictable stress (CUS) protocol used in the present study 
(adapted  from48). Note that fish undergoing 3-day behavioral testing on specific weeks 1–5 were separated 
from stress cohort, excluded from CUS procedures after behavioral assays, and euthanized for sampling next 
day after the last behavioral test of the battery (ZTI) was administered. NTT the novel tank test, LDT the light/
dark test, ST shoaling test, ZTI the zebrafish tail immobilization test. *Adding 0.5 L of ice to the hometank. 
**Adding 20 novel plastic children kinder toys to the hometank. ***Simultaneous exposure of all cohort to air 
in the net (30 s, followed by a 1-min rest, repeated 5 times). ****Exposure to loud white noise sound using the 
40-W sound speakers. *****Exposure to 5 mL alarm pheromone (per L of water) extracted from additional 
intact fish as  in40, 68.
CUS days Specific CUS stress procedures
Behavioral tests and 
sampling
1 Tank change → local hypothermia*
2 Net chasing (10 min) → novel objects added to the hometank **(6 h)
3 Crowding (2 h) → Air exposure ***
4 Darkness (24 h)
5 Food deprivation (24 h)
6 Water change → noise exposure in unfamiliar tank **** (4 h)
7 Alarm pheromone ***** → remixing cohorts Week 1 NTT/LDT
8 Bright light (4 h) → novel objects (8 h) ST
9 Crowding (2 h) + remixing cohorts → net chasing (15 min) ZTI
10 Noise exposure in unfamiliar tank **** (5 h) → water change Euthanasia, sampling
11 Darkness (24 h)
12 Food deprivation (24 h)
13 Air exposure → local hypothermia
14 Bright light (6 h) → alarm pheromone Week 2 NTT/LDT
15 Noise exposure in an unfamiliar tank (6 h) → remixing cohorts ST
16 Novel objects (10 h) → shallow water (8 h) + water change ZTI
17 Crowding (3 h) + remixing cohorts → alarm pheromone Euthanasia, sampling
18 Darkness (24 h)
19 Food deprivation (24 h)
20 Net chasing (20 min) → local hypothermia
21 Bright light (8 h) → alarm pheromone Week 3 NTT/LDT
22 Overcrowding (12 h) → remixing cohorts ST
23 Exposure to air → shallow water (10 h) + water change ZTI
24 Noise exposure in unfamiliar tank (8 h) → alarm pheromone Euthanasia, sampling
25 Darkness (24 h)
26 Food deprivation (24 h)
27 Bright light (12 h) → shallow water (12 h)
28 Tank change + remixing cohorts → air exposure Week 4 NTT/LDT
29 Food deprivation (24 h) → local hypothermia ST
30 Bright light (14 h) → net chasing (30 min) ZTI
31 Alarm pheromone → novel objects (18 h) Euthanasia, sampling
32 Darkness (24 h)
33 Food deprivation (24 h)
34 Noise exposure in unfamiliar tank (10 h) → overcrowding (12 h)
35 – Week 5 NTT/LDT
36 – ST
37 – ZTI
38 – Euthanasia, sampling
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(Table 2). Furthermore, significant stress vs. control week differences were found for weeks 2–4 (Fig. 3, Supple-
mentary Table S5). Finally, GZLM2 analyses revealed significant group effects for 5-HIAA levels, with significant 
fluoxetine vs. control and vs. stress differences for post-hoc Tukey’s test (Table 3). GZLM2 also revealed altered 
5-HIAA/serotonin ratios, with fluoxetine significantly differing vs. control and stress, as assessed by the Tukey’s 
test pairwise comparisons (Table 3).
The Gamma-test revealed 13 significant correlations (Table 4), including cross-test correlations (e.g., NTT 
distance and ST inter-fish distance, r =  − 0.55, p < 0.05) and correlations between behavioral and neurochemical 
endpoints (e.g., the ZTI time spent active and the 3,4-dihydroxyphenylacetic acid (DOPAC)/dopamine ratio, 
r = 0.48, p < 0.05). As already mentioned, no effect as a predictor in GZML1 analyses found no behavioral battery 
Table 2.  Summary of the Wald Chi-square test results (ANOVA Type II) for generalized linear model 
(GZLM1; Supplementary Table S2) using week (1–5), group (control vs. stress) and their interaction effects 
as predictors (GZLM1) in the zebrafish 5-week chronic unpredictable stress (CUS) model used in the present 
study. Behavioral endpoints were assessed in the novel tank test (NTT), light–dark test (LDT), shoaling 
test (ST) and the zebrafish tail immobilization test (ZTI), also see Figs. 2 and 3, Table 3 and Supplementary 
Tables S1–S5 for details. NS no significant differences (p > 0.05), DOPAC 3,4-dihydroxyphenylacetic acid, 
5-HIAA 5-hydroxyindoleacetic acid, HVA homovanillic acid. Df degree of freedom.
Factors Df χ2 P Factors Df χ2 p
NTT distance travelled, cm NTT time spent not moving, s
Week 4.00 11.12 0.03 Week 4.00 21.09  < 0.01
Group 1.00 52.03  < 0.01 Group 1.00 9.51  < 0.01
Week × group 4.00 9.52 NS Week × Group 4.00 11.95 0.02
NTT time spent in top, s NTT number of top entries
Week 4.00 148.85  < 0.01 Week 4.00 14.01 0.01
Group 1.00 149.59  < 0.01 Group 1.00 0.25 NS
Week × group 4.00 11.76 0.02 Week × group 4.00 18.33  < 0.01
NTT latency to enter top, s ZTI time spent active, s
Week 4.00 17.63  < 0.01 Week 4.00 10.67 0.03
Group 1.00 27.06  < 0.01 Group 1.00 0.60 NS
Week × group 4.00 10.38 0.03 Week × group 4.00 19.80  < 0.01
LDT time spent in light, s LDT number of light entries
Week 4.00 2.45 NS Week 4.00 6.50 NS
Group 1.00 31.54  < 0.01 Group 1.00 2.47 NS
Week × group 4.00 17.11  < 0.01 Week × group 4.00 2.70 NS
ST distance to surface, cm ST inter-fish distance, cm
Week 4.00 12.26 0.02 Week 4.00 5.36 NS
Group 1.00 1.31 NS Group 1.00 12.76  < 0.01
Week × group 4.00 34.86  < 0.01 Week × group 4.00 5.46 NS
Dopamine, pg/mg DOPAC/dopamine ratio
Week 4.00 11.02 0.03 Week 4.00 10.67 0.03
Group 1.00 0.88 NS Group 1.00 0.37 NS
Week × group 4.00 2.77 NS Week × group 4.00 3.80 NS
DOPAC, pg/mg 5-HIAA, pg/mg
Week 4.00 3.51 NS Week 4.00 7.19 NS
Group 1.00 0.40 NS Group 1.00 2.52 NS
Week × group 4.00 3.40 NS Week × group 4.00 14.73 0.01
5-HIAA/serotonin ratio Serotonin, pg/mg
Week 4.00 6.53 NS Week 4.00 4.23 NS
Group 1.00 2.70 NS Group 1.00 0.54 NS
Week × group 4.00 18.22  < 0.01 Week × group 4.00 5.67 NS
HVA/dopamine ratio HVA, pg/mg
Week 4.00 7.06 NS Week 4.00 3.47 NS
Group 1.00 2.59 NS Group 1.00 2.34 NS
Week × group 4.00 5.18 NS Week × group 4.00 5.97 NS
Norepinephrine, pg/mg
Week 4.00 13.76 0.01
Group 1.00 3.79 NS
Week × group 4.00 4.56 NS
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exposure impact on neurochemistry (Supplementary Table S6). Because no differences were found for neuro-
chemical endpoints between CUS sub-groups of behaviorally tested vs. naive untested fish, combining these 
two sub-groups into one cohort for analyses was justifiable (see Supplementary Table S6 for statistical details).
Our CNS genomic analyses revealed a total of 196 genes (130 downregulated and 66 upregulated) differen-
tially expressed in stressed vs. control fish (Figs. 4, 5, Supplementary Table S8, Figs. S1–S5), as well as 49 genes 
(34 downregulated and 15 upregulated) differentially expressed in fluoxetine vs. control groups. Overall, 35 genes 
(25 downregulated and 10 upregulated) were differentially co-expressed in the same direction in the stressed 
and fluoxetine (vs. control) groups, likely representing CUS-related genes resistant to antidepressant treatment 
(Figs. 4, 5, Supplementary Table S8, Figs. S1–S5). Finally, differential expression in fluoxetine vs. control fish 
involved 18 genes (3 downregulated and 15 upregulated), among which 9 (2 downregulated and 7 upregulated) 
genes have already been noted as differentially expressed (but in the opposite direction) in stress vs. control fish, 
thus likely representing a set of genes whose expression was altered by CUS but became normalized/rescued by 
the antidepressant treatment.
Table 3.  Summary of post-hoc Tukey’s test results for significant Wald Chi-square test (ANOVA Type II) for 
generalized linear model (GZLM1; Supplementary Table S6) using group (control, stress and fluoxetine) at 
week 5 as predictor (GZLM2) in the zebrafish 5-week chronic unpredictable stress (CUS) model used in the 
present study. Behavioral endpoints were tested in the novel tank test (NTT), light–dark (LDT), shoaling (ST) 
and zebrafish tail immobilization (ZTI) tests, also see Figs. 2, 3, Table 2 and Supplementary Tables S1–S5 
for details. NS no significant differences (p > 0.05), DOPAC 3,4-dihydroxyphenylacetic acid, 5-HIAA 
5-hydroxyindoleacetic acid, HVA homovanillic acid, Df degree of freedom.
Endpoints Df χ2 p Groups compared M 95% confidence interval z.test p
Novel tank test (NTT)
Distance, cm
2.00 13.22  < 0.01 Control–fluoxetine  − 28.33 [− 269.06, 212.41]  − 0.23 NS
Control–stress  − 400.19 [− 640.93, − 159.45]  − 3.26 0.001
Fluoxetine–stress  − 371.86 [− 612.60, − 131.13]  − 3.03 0.002
Time spent not moving. s 2.00 2.95 NS
Time spent top, s
2.00 34.81  < 0.01 Control–fluoxetine 41.10 [− 6.39, 88.59] 1.70 NS
Control–stress 139.13 [91.64, 186.61] 5.74  < 0.001
Fluoxetine–stress 98.03 [50.54, 145.51] 4.05  < 0.001
Number of top entries 2.00 2.74 NS
Latency to enter top, s
2.00 17.99  < 0.01 Control–fluoxetine  − 31.44 [− 94.75, 31.88]  − 0.97 NS
Control–stress  − 131.20 [− 194.52, − 67.89]  − 4.06  < 0.001
Fluoxetine–stress  − 99.77 [− 163.08, − 36.45]  − 3.09 0.002
Light–dark test (LDT)
Time spent in light, s 2.00 0.41 NS
Number of light entries 2.00 0.53 NS
Shoaling test (ST)
Inter-fish distance, cm
2.00 10.02 0.01 Control–fluoxetine 0.09 [− 0.17, 0.34] 0.67 NS
Control–stress 0.39 [0.14, 0.64] 3.01 0.003
Fluoxetine–stress 0.30 [0.05, 0.56] 2.35 0.019
Distance to surface, cm 2.00 3.39 NS
Zebrafish tail immobilization test (ZTI)
Time spent active, s 2.00 0.40 NS
Neurochemical endpoints
Dopamine, pg/mg 2.00 0.76 NS
DOPAC/dopamine ratio 2.00 0.43 NS
DOPAC, pg/mg 2.00 1.75 NS
5-HIAA, pg/mg
2.00 17.69  < 0.01 Control–fluoxetine 0.84 [0.37, 1.30] 3.52  < .0001
Control–stress  − 0.05 [− 0.52, 0.41]  − 0.23 NS
Fluoxetine–stress  − 0.89 [− 1.35, − 0.42]  − 3.75  < 0.001
5-HIAA/serotonin ratio
2.00 10.82  < 0.01 Control–fluoxetine 0.89 [0.30, 1.47] 2.98 0.003
Control–stress 0.27 [− 0.38, 0.93] 0.82 NS
Fluoxetine–stress  − 0.62 [− 1.15, − 0.08]  − 2.27 0.023
Serotonin, pg/mg 2.00 3.09 NS
HVA/dopamine ratio 2.00 3.58 NS
HVA, pg/mg 2.00 3.21 NS
Norepinephrine, pg/mg 2.00 1.05 NS
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Table 4.  Correlations matrix of group × week subgroups for behavioral and neurochemical endpoints 
assessed by the Goodman and Kruskal’s gamma correlation test. Statistically significant correlations are bolded 
(p < 0.05). DOPAC 3,4-dihydroxyphenylacetic acid, 5-HIAA 5-hydroxyindoleacetic acid, HVA homovanillic 
acid.
Endpoints 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1. Time not moving, s  − 0.6 0.2 0.3 0.3  − 0.3 0.1 0.2 0.0  − 0.2 0.2 0.2 0.2  − 0.3  − 0.2 0.0
2. Distance traveled, cm  − 0.4  − 0.6  − 0.5 0.2 0.0 0.0 0.0 0.0 0.1  − 0.2 0.1 0.1 0.1  − 0.1
3. Time spent top, s 0.4 0.4  − 0.3  − 0.4  − 0.2  − 0.2 0.2  − 0.3 0.1  − 0.2 0.2  − 0.3 0.3
4. Time in light, s 0.1  − 0.1  − 0.1  − 0.4  − 0.1 0.0  − 0.5 0.0 -0.1 0.0  − 0.1 0.2
5. Inter-fish distance, cm  − 0.3  − 0.2 0.0 0.0 0.0 0.0 0.2  − 0.2 0.1  − 0.1 0.1
6. Distance to surface, cm 0.3 0.0 0.2 0.3 0.2 0.3 0.2 0.2 0.4 0.2
7. Time active, cm 0.1 0.2 0.0 0.3 0.3 0.4  − 0.1 0.5 0.1
8. Norepinephrine, pg/mg 0.3 0.0 0.7 0.1 0.4  − 0.2 0.0  − 0.3
9. DOPAC, pg/mg 0.3 0.5 0.3 0.5 0.1 0.6 0.1
10. 5-HIAA, pg/mg 0.2 0.4 0.2 0.6 0.1 0.2
11. Dopamine, pg/mg 0.2 0.6  − 0.1 0.1  − 0.2
12. HVA, pg/mg 0.2 0.4 0.4 0.6





16. HVA/dopamine ratio 1
Table 5.  Top 10 nodes analyzed using the double screening scheme (DSS) analysis, combining the density 
of maximum neighborhood component (DMNC) and maximum neighborhood component (MNC, see 
“Methods” section for details; DMNC||MNC), degree, or bottleneck methods, for networks of constructed 
protein–protein interactions (PPI; STRING database) and gene co-expression (GE; GeneMANIA; see 
“Methods” section and Fig. 5 for details).
Genes or 
Proteins DMNC MNC Genes or Proteins Degree Genes or Proteins Bottle-neck
STRING (PPI)
tpm4b 0.81 23 isg15 32 isg15 31
tnni2b.1 0.96 20 ttnb 29 actc1b 24
myh6 0.87 20 actc1b 28 Ttnb 22
tnnc2 0.84 20 stat1b 26 saga 11
tnni2a.1 1.00 19 tpma 25 trim35-29 10
mylz3 0.88 19 tpm3 24 stat1b 9
ns:zf-e68 0.83 18 tpm4b 23 ENSDARG00000004953 9
neb 0.96 17 actn3b 23 myhz1.1 9
tnnt2a 0.98 16 myl1 21 ptprc 7
tnnt2d 0.94 15 usp18 21 arr3a 7
GeneMANIA (GE)
mov10b.1 0.82 24 CABZ01073795.1 36 mxa 13
cd74b 0.78 24 mxa 28 CABZ01073795.1 11
stat1b 0.77 24 isg15 25 si:ch211-1a19.3 10
si:dkeyp-9d4.2 0.75 23 stat1b 25 slc4a1a 10
ctss2.1 0.73 23 si:ch211-1a19.3 25 irbp 7
isg15 0.91 22 irf7 24 cd74b 6
ponzr1 0.90 22 psme2 24 irf7 5
psme2 0.86 22 mov10b.1 24 ctss2.1 5
zgc:152791 0.75 22 cd74b 24 si:ch211-24o10.6 5
irf7 0.91 21 si:dkeyp-9d4.2 24 grap2b 5
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The Generally Applicable Gene-set Enrichment (GAGE, see the “Methods” section for details) of these results 
(Supplementary Table S9) revealed 87 Gene Ontology (GO) and 10 Kyoto Encyclopedia of Genes and Genomes 
(KEGG)-listed pathways differentially expressed in stressed vs. control fish, forming 13 essential GO and 8 
KEGG gene sets. For fluoxetine-treated vs. control fish, GSEA yielded 68 GO pathways and 6 KEGG pathways, 
clustered into 9 GO and 5 KEGG essential pathways. Fluoxetine vs. stressed fish GAGE analysis revealed 19 GO 
and 3 KEGG pathways, organized in 7 and 3 essential sets respectively. Finally, topological analyses (focusing on 
potential importance of proteins and genes as therapeutic targets) of both these genes and their protein products 
linked some hub nodes, such as tpm4b, isg15, mov10b.1, CABZ01073795.1, mxa, to both zebrafish CUS and its 
treatment (Fig. 4, Table 5 and Supplementary Fig. S4, S5).
As shown in Fig. 6, the qualitative real-time polymerase chain reaction (qRT-PCR) analyses of the same 
samples successfully validated the RNA sequencing results reported above (see also Supplementary Table S10 
for statistical data). Specifically, among several reference genes we selected for such validation, isg15 significantly 
reduced expression in both stress and fluoxetine groups vs. control, the tpm4b expression increased in stressed vs. 
control groups, saga expression decreased in stressed vs. fluoxetine group, and otx5 in stressed vs. both control 
and fluoxetine groups (Fig. 6, Supplementary Table S10). The genes for qRT-PCR analyses were chosen based 
on their hubness in core PPI groups and on different expression patterns between groups (see the “Methods” 
section for details).
Figure 2.  Weekly dynamics of behavioral alterations induced by chronic unpredictable stress (CUS) exposure 
and fluoxetine treatment in adult zebrafish tested in the novel tank test (time spent in top and distance traveled), 
the light–dark test (time spent in light), shoaling test (average inter-fish distance and distance to water surface) 
and the zebrafish tail immobilization test (ZTI, time spent active). Data is represented as mean ± S.E.M. (n = 20 
in weeks 1–3 and n = 15 in weeks 4–5), *p < 0.05 control vs. stress, post-hoc Tukey’s test for significant Wald 
Chi-squared test (ANOVA Type II) for GZLM1 for group (control and stress), week (1–5) and their interaction 
as predictors, #p < 0.05 stress vs. control group and $p < 0.05 fluoxetine vs. stress group, post-hoc Tukey’s test 
for significant Wald Chi-squared test ANOVA (Type II) for GZLM2 for group (control, stress and fluoxetine) 
at week 5 as predictor. Graphs were constructed using the ggplot2 R  package137, also see Tables 2 and 3 and 
Supplementary Tables S1–S5 for statistical details.
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Discussion
The present report is the first large-scale study that explored in-depth complex weekly behavioral and neuro-
chemical dynamics of CUS-evoked states in adult zebrafish, testing a wide range of anxiety-, social and despair-
like behaviors. We also paralleled these data with a genome-wide brain transcriptomic screening of the 5-week 
CUS effects, and performed in-silico modeling of molecular networks associated with the identified differentially 
expressed genes.
Our behavioral findings can be briefly summarized as follows: first, overt NTT anxiety (reduced top explora-
tion) was the most stable behavioral effect observed weekly following the CUS protocol here (Fig. 2, Tables 2, 3). 
In contrast, the LDT behavior was insensitive to anxiety-like changes at weeks 4 and 5, corroborating a putative 
lesser sensitivity of this test (than NTT) to  anxiety49,50. Moreover, the ZTI activity decreased at week 1, increased 
at week 3, and remained unaltered at other CUS weeks (Fig. 2, Table 2), suggesting rather complex interactions 
between anxiety- and despair-like phenotypes in zebrafish (also see complex CUS effects on despair in rodent 
 models51–54). Finally, shoals of the stressed fish displayed shorter inter-fish distance, consistent with increased 
NTT anxiety-like behavior in fish observed here (Fig. 2, Table 2) and reported previously for zebrafish stress 
models in the  literature40,47,50,55,56.
Chronic fluoxetine reversed most of the CUS-evoked behavioral phenotypes in the present study (Fig. 2), thus 
resembling anti-stress anxiolytic/antidepressant effects observed clinically (Table 3). Notably, there were overt 
fluctuations in baseline behaviors in control fish over time (Fig. 2), likely due to some environmental influences 
beyond of experimenter’s control (e.g., atmospheric pressure) that would affect all study groups equally. However, 
this observation parallels daily variance of zebrafish behavior reported  earlier57, hence corroborating the overall 
behavioral validity of the present study.
Summarized in Fig. 3 and Tables 2 and 3, neurochemical analyses strongly implicate the serotonergic sys-
tem in zebrafish CUS, consistent with similar serotonergic responses in rodent  CUS58–60 and human affec-
tive  disorders61–64, and suggesting shared, evolutionarily conserved serotonergic mechanisms underlying CUS. 
Indeed, we found reduced levels of a serotonin metabolite 5-HIAA and the 5-HIAA/serotonin ratios, as well as 
their increase at week 2 of stress. The 5-HIAA/serotonin ratio is common biomarker of CNS serotonergic activity, 
reflecting the activation of serotonergic neurons and their serotonin release, followed by its  metabolization65,66. 
Interestingly, our findings also parallel reduced 5-HIAA in 15-day zebrafish CUS reported in a different study 
 earlier67. Thus, altered 5-HIAA levels and the 5-HIAA/serotonin ratios only emerged from week 2 in the present 
study—an important methodological observation suggesting that shorter (e.g., 1-week) protocols based on CUS 
exposure may be insufficient for (or less capable of) evoking pathological alterations in the serotonergic system 
of zebrafish.
Figure 3.  Weekly dynamics of neurochemical alterations induced by chronic unpredictable stress 
(CUS) exposure and fluoxetine treatment, assessed by HPLC in the whole-brain samples of adult zebrafish 
(n = 10). Data are represented as mean ± S.E.M. *p < 0.05 control vs. stress, post-hoc Tukey’s test for significant 
Wald Chi-squared test ANOVA (Type II) for GZLM1 for group (control and stress), week (1–5) and their 
interaction as predictors, #p < 0.05 stress vs. control group and $p < 0.05 fluoxetine vs. stress group and &p < 0.05 
fluoxetine vs. control, post-hoc Tukey’s test for significant Wald Chi-squared test ANOVA (Type II) for GZLM2 
using group (control, stress and fluoxetine) at week 5 as predictor. Graphs were constructed using the ggplot2 R 
 package137, also see Tables 2 and 3 and Supplementary Tables S1–S5 for statistical details.
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To further integrate behavioral and neurochemical CUS-evoked alterations in zebrafish, we performed cor-
relational analyses of behavioral and neurochemical endpoints, comparing all average values for each endpoint 
at each individual week of CUS (Table 4). While brain dopamine levels negatively correlated with the LDT time 
in light, the DOPAC/dopamine ratio positively correlated with the ZTI time spent active (Table 4), supporting 
the link between the DOPAC/dopamine ratio and zebrafish despair-like behavior, already noted in this  test68. 
NTT distance negatively correlated with NTT time not moving, LDT time in light and the ST average inter-fish 
distance (Table 4). However, using group means values (instead of individual fish values) could somewhat limit 
such analyses, thus representing only pilot correlational findings. Moreover, like genomic assays, neurochemical 
analyses performed here involved whole-brain samples (rather than individual brain regions), likely representing 
a less sensitive approach for probing potential region-specific changes in neurochemistry and genomics, therefore 
necessitating further studies of region-specific changes during CUS in zebrafish.
Furthermore, multiple zebrafish CUS studies have shown increased anxiety following a 2-week (or longer) 
CUS  protocols47,48,56,67, consistent with the present findings (Fig. 2, Tables 2, 3). However, some other reports 
failed to evoke overt  anxiety69, raising questions of whether CUS protocol was indeed properly applied in such 
studies (e.g.,  see70,71 for a recent discussion of challenges with data reliability and replicability in zebrafish behav-
ioral models). Thus, further research is needed, for example, to compare zebrafish that received CUS protocols 
that would differ in the numbers of stressors, their severity and/or duration.
Nevertheless, zebrafish genomic data, analyzed here using different bioinformatic methods (see “Methods” 
section for details), revealed major genomic changes associated with stress exposure and its drug treatment 
(Figs. 4, 5, Table 5, Supplementary Tables S7, S8, and Supplementary Figs. S4, S5). Overall, stress induced overt 
CNS gene expression changes, differentially affecting genes involved in inflammation/cytokine-related signaling 
pathways, Mitogen-Activated Protein Kinase (MAPK) signaling and receptor tyrosine kinases, such as signal 
transducer and activator of transcription (stat) 1b and 4, interleukin 21 receptor (il21r), radical S-adenosyl 
Figure 4.  The network of protein–protein interactions (PPI) constructed for differentially expressed genes 
(found in all analyses) using the STRING online  database151 (see “Methods” section and Supplementary 
Figs. S1–S3 for details). Genes represented as numbers refer to “ENSDARG000000*”, where * denotes the last 
5 digits of the Ensembl gene names (ID). The network was visualized using the CytoScape  application149,150. 
SvC stress vs. control, FvC fluoxetine vs. stress, SFvC differentially expressed in both SvC and FvC (in same 
l2fc direction), FvS fluoxetine vs. stress, SvCF differentially expressed in SvC and FvS (in opposite directions, 
color refers to the direction of FvS expression change), Additional—20 proteins with the highest interaction 
score in STRING for suggested PPI networks. Letters denote several clusters of genes, including (A) arrestins 
and G protein-coupled receptors (GPCRs) related genes, (B) ubiquitin-related genes and their inflammatory 
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methionine domain-containing protein 2 (rsad2), janus kinase 3 (jak3), zeta-chain-associated protein kinase 
70 (zap70) and suppressor of cytokine signaling (socs) 1a and 3a, receptor tyrosine kinase-like orphan receptor 
1 (ror1), thymocyte-expressed-molecule (themis) and altered pathways (GO:0004713 protein tyrosine kinase 
activity; dre04010 MAPK signaling pathway; Fig. 4 and 5, Supplementary Figs. S4, and S5). Similarly to previ-
ous studies, we also found changes in the expression of interferon inducible proteins IFI6/IFI27-like associated 
genes and  pathways69 (Supplementary Fig. S5). 
Furthermore, CUS upregulated various cytoskeletal and cell motility-related brain genes, such as encoding 
myosins (light chain 1 and heavy polypeptide 1.1 and 6) and troponins (T2a, T2d and 2a.1), also disturbing the 
expression of ubiquitin-related genes, such as interferon-stimulated gene 15 ubiquitin-like modifier (isg15), 
ubiquitin E3 ligases (si:dkey-40c23.2) and other associated genes (zgc:163,136 ubiquitin-protein transferase; 
Figs. 4, 5, Supplementary Table S8, and Figs. S4, S5). Notably, these ubiquitin-related genes are linked to various 
interferon-associated genes, and isg15 interacts and co-expresses with multiple other genes, thus representing 
the strongest hub gene found for CUS here (Fig. 5, Table 5). Stress also lowered the expression of dre04744 
Phototransduction (see further), and disturbed endocrine (especially steroid) function-related genes, increas-
ing the vitellogenin vtg1, -2 and -5 genes expression (see further). Finally, CUS exposure affected the RNA 
processing-related pathways, including GO:0006397 mRNA processing, GO:0003735 structural constituent of 
ribosome, dre03010 ribosome, and dre03040 spliceosome and cell metabolism, GO:0009199 ribonucleoside 
triphosphate metabolism, dre01200 carbon metabolism, dre00010 glycolysis/gluconeogenesis, and dre00983 
drug metabolism/other enzymes.
In contrast, fluoxetine normalized the expression of most of these CUS-affected genes, sharing with stress only 
35 out of 196 ‘stress’ genes, mostly representing key inflammatory hubs associated with cytokine activity (e.g., 
isg 15, stat1b, jak3, Figs. 4, 5, Supplementary Table S8 and Fig. S1–S5). Similarly, while the expression of genes of 
some pathways was restored by fluoxetine, others remained differentially expressed (e.g., RNA-related pathways 
dre03010 Ribosome, dre03040 spliceosome, GO:0034660 ncRNA metabolic process, GO:0003735 structural 
constituent of ribosome and metabolic pathways, dre01200 carbon metabolism, GO:0009144 purine nucleoside 
triphosphate metabolism, GO:0019752 carboxylic acid metabolism, Supplementary Table S9). Furthermore, the 
GO:0006955 immune response expression decreased, thus potentially contributing to the overall reduction of 
activity of genes of cytokine-related pathways in the fluoxetine-treated fish.
Figure 5.  Gene co-expression (GE) network constructed for differentially expressed genes (found in all 
analyses) using the  GeneMANIA155–158 online database (see the “Methods” section, and Supplementary 
Figs. S1–S3 for details of treatment and network construction). The network was graphically presented using the 
CytoScape  application149,150. SvC stress vs. control, FvC fluoxetine vs. stress, SFvC differentially expressed in both 
SvC and FvC (in same l2fc direction), FvS fluoxetine vs. stress, SvCF differentially expressed in both SvC and FvS 
(in the opposite direction, color refers to the direction of FvS expression change), Additional—20 genes with the 
highest co-expression score in GeneMANIA for suggested PPI networks. (A) fluoxetine vs. stress-related genes 
that are commonly co-expressed.
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To better understand fluoxetine effects on stress pathogenesis, we also compared the fluoxetine and CUS 
groups, revealing 18 differentially expressed genes, 9 of which were found in CUS vs. control fish, thus proving 
normalizing their expression by fluoxetine. Analyses of their PPI networks show that most of such differentially 
expressed genes are interrelated, and form a small functional sub-network that includes orthodenticle homolog 
5 (otx5), arrestin 3a (arr3a), s-antigen (saga), and GPCR genes (gngt1, gnb3b and gpr183a).
In general, inflammation is an important factor in affective  pathogenesis72–76. Complementing clinical data, 
animal inflammation-related models of affective disorders are widely used to recapitulate affective  pathogenesis24. 
The 5-week CUS protocol used here has recently been shown to induce major alterations in both inflammatory 
and anti-inflammatory cytokine networks, all corrected by  fluoxetine48. Similarly, the present CUS study revealed 
global brain expression changes in genes involved in inflammation, whereas fluoxetine treatment predictably 
normalized most of these genomic effects (Figs. 4, 5, Supplementary Table S8, and Figs. S1–S5).
The role of sex-related genes, especially estrogens, in the pathogenesis of depression is also thoroughly dis-
cussed in the  literature77–80. In fish, vitellogenin is an important biomarker of endocrine disruption that is 
sensitive to estrogen  exposure81,82. CNS expression of vitellogenin genes vtg1, -2 and -5 rose in the GO:0005179 
‘hormone activity’, GO:0000003 ‘reproduction’ and other related pathways, further implying endocrine deficits 
in stressed fish, and suggesting that changes in the expression of some endocrine system genes may contribute 
to affective pathogenesis. Moreover, CUS applied here strongly (l2fc = 8.4) increased the expression of adhesion 
GPCR G4b (adgrg4b), whereas fluoxetine restored it to control levels (Fig. 4, 5, Supplementary Table S8, and 
Figs. S4, S8). Interestingly, adhesion G protein–coupled receptors (aGPCRs) represent an important, but 
understudied family of proteins that participate in both cell adhesion and signaling  functions83. Although the 
physiological roles of most of aGPCRs are poorly understood, some of them have already been linked to brain 
 disorders84, since, for example, Adgrb2 knockout mice display reduced depression-like behavior and enhanced 
hippocampal cell  proliferation85.
Arrestins are a small family of highly homologous adaptor proteins that function as regulators of the GPCR 
signaling, supporting their internalization and activating independent (e.g., tyrosine kinase Src and MAPK-
related)  pathways86–88. The activity of arrestins in-vivo is important, given biased GPCR ligands that activate G 
protein- and arrestins-related pathways with different  efficiency89. Arrestins have also been suggested as potential 
targets for treating affective  pathologies90, since leukocytes of depressed patients show lower levels of beta-
arrestin-1, whereas antidepressant treatment increases these levels in both  rats91 and  humans92. Furthermore, 
beta-arrestins may modulate central serotonergic system, including serotonin-induced activation of ERK1/2 by 
serotonin 5-HT2A receptors, and since serotonin and 2,5-dimethoxy-4-iodoamphetamine (DOI) act through 
Figure 6.  Qualitative real-time polymerase chain reaction results of the last (fifth) week of CUS showing 
differential expression of selected four reference genes in adult zebrafish brain samples with significant 
expression differences detected previously by the RNA-seq. Data is analyzed and represented using the Pfaffl 
method. *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls or vs. the group connected by a horizontal line, post-hoc 
Dunn’s test for pairwise comparisons for significant Kruskal–Wallis data (see Supplementary Table S10 for 
details). Graphs were constructed using the ggplot2 R  package137.
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distinct (beta-arrestin-2-dependent and independent, respectively) mechanisms, to induce mouse head twitch 
 responses93.
Notably, the biological function of arrestins depends on their ubiquitination and deubiquitination, which 
determine the efficiency of receptors internalization, the fate of the arrestin-receptor complex, and the signaling 
cascades it  activates94. Similarly, ubiquitination also plays a role in antidepressant  activity95, since citalopram, 
imipramine, desipramine and moclobemide all increase mRNA expression of beta-arrestin-2 in C6 rat glioma 
cells, but reduce its protein levels via rapid ubiquitinylation that promotes proteasomal  degradation95. In line 
with this notion, we found altered expression of ubiquitin- and arrestins-related genes (e.g. isg15, dre04744 
Phototransduction) in the CUS group, with a subtle increase in the expression of two arrestins- (saga, arr3a) and 
related pathways (dre04744 phototransduction, GO:0007601 visual perception expression) following fluoxetine 
treatment (Figs. 4, 5, Supplementary Tables S7, S8, and Figs. S4, S5). This further suggests the putative role of 
arrestins and their ubiquitination in affective pathogenesis and antidepressant treatment, with multiple potential 
translational implications, thus meriting further studies in other CNS stress models and other species.
In conclusion, our results show that CUS induced complex behavioral and neurochemical phenotypes in 
zebrafish that dynamically evolve over a 5-week battery. While some phenotypes, such as NTT anxiety, were 
relatively stable across time, other responses (e.g., ST shoaling and ZTI despair-like behaviors, as well as sero-
tonin metabolism) may fluctuate weekly within the CUS battery. Finally, our genomic analyses revealed altered 
brain expression of multiple inflammation-related genes following CUS, partially rescues by chronic fluoxetine 
treatment. Collectively, these findings support zebrafish as a valuable translational tool to study stress-related 
pathologies. For example, while CUS exposure induced pronounced anxiety and serotonergic deficits in zebrafish 
(paralleling rodent and clinical studies), chronic fluoxetine exposure rescued most of these effects. Comple-
menting these physiological findings, the present transcriptomic analyses further implicate neuroinflamma-
tion, structural neuronal remodeling and the arrestins/ubiquitin regulation, in both stress pathology and its 
mechanisms of treatment.
Methods
Animals and housing. Adult, 3–5 months old wild-type short-fin experimentally naïve zebrafish (approxi-
mately 50:50 male:female ratio) were obtained from a local distributor (Axolotl, Ltd., St. Petersburg, Russia) and 
housed for at least 3 weeks in standard conditions in groups of 10–15 fish in 4-L tanks (2.5–3.75 fish/L) at the 
Aquatic Facility of Almazov National Medical Research Center (St. Petersburg, Russia) in the ZebTec Active Blue 
Stands with Water Treatment Unit (Tecniplast, West Chester, USA), filled with filtered system water maintained 
at 27 ± 0.5 °C and pH 7.4. The illumination in the holding room (950–960 lx) was provided by 18-W fluorescent 
light tubes with a 12/12 light/dark cycle (unless specified otherwise in the CUS protocol, Table 1). All fish were 
fed twice a day with small food pellets Neon Micro Granules for fish size 1–2 cm long (Dajana Pet, Bohuňovice, 
Czech Republic) according to the zebrafish feeding  standards96, unless specified otherwise in the CUS protocol 
detailed in Table 1. All fish belonged to the same baseline population and were allocated to the experimental 
groups randomly using a random number generator, and were acclimated at least 2 weeks before the experi-
ments. As the animals were involved in the study, see Ethical Confirmation statement for approval and ethical 
details. All animals tested were included in final analyses, without removing outliers. All experiments were per-
formed as planned, and all analyses and endpoints assessed were included without omission.
Chronic unpredictable stress (CUS). The study experimental design is summarized in Fig. 1 and Table 1, 
and utilized a 5-week CUS battery, as described  previously48. The control fish were housed similarly to the 
experimental cohort, but remained experimentally naïve for the entire study duration, as  in48. On Day 28, the 
stressed fish cohort was divided into two groups (Stress and Fluoxetine) that both continued to receive stressors 
(Table 1), with the latter group also receiving chronic fluoxetine (0.1 mg/L) during the last 11 days of the study. 
Fluoxetine was selected here as a classical SSRI antidepressant with well-established clinical  activity97–99 and 
proven efficacy in both  rodent100–103 and zebrafish  models40,46,48,104,105. The dose and the treatment duration for 
the drug were selected based on our previous zebrafish CUS  studies48.
Behavioral testing. Behavioral testing of parallel zebrafish cohorts with varying stress durations (from 1- 
to 5-week CUS) was performed weekly within a 3-day test battery one day after the last CUS stressor was applied 
(Fig. 1, Table 1). Behavioral analyses were performed between 9:00 am and 6.00 pm (NTT, ST and ZTI between 
9:00–12:00 am, LDT between 3:00–6:00 pm) by individually exposing zebrafish to a standard behavioral battery 
consisting of the NTT (Day 1 morning), LDT (Day 1 afternoon), ST (Day 2 morning) and the ZTI test (Day 
3 morning), as shown in Fig. 1. Testing zebrafish one day after the last stressor application was chosen here in 
order to avoid potential confounding ‘immediate’ effects of acute stressors, thus focusing instead on baseline 
persistent effects of chronic stress per se. Fish that underwent behavioral testing were excluded from CUS proto-
col on those respective CUS days, did not receive stressors during the testing and were euthanized after the last 
behavioral test (ZTI). The 5-week CUS battery was chosen here as an established model in our laboratory, effi-
ciently inducing pronounced behavioral and molecular changes in  zebrafish48 consistent with other CUS proce-
dures. Prior to behavioral testing, all fish (n = 20 at weeks 1–3, and n = 15 at weeks 4–5, Fig. 1) were transported 
from the holding room and acclimated to the testing room for 2 h. After behavioral testing, fish were returned 
to their respective hometanks and placed back to the aquatic housing system. The specific test battery used was 
chosen here because although zebrafish generally display a relatively weak sensitivity to the test battery  effect106, 
the battery was organized in the order of stress intensity, i.e., from lower- to higher-stress, aiming to reduce any 
potential prior test experience effects, as suggested  in32.
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The NTT was chosen here as the most sensitive and commonly used behavioral test to assess anxiety and 
locomotion in  zebrafish49,107, performed similarly  to108. The NTT apparatus consisted of a 2-L acrylic rectangu-
lar tank (20 height × 20 length × 5 width cm) filled with water up to 19 cm, and divided into two equal virtual 
horizontal portions. Back and lateral sides of the tank were covered with nontransparent white covers (fixed to 
the outside walls), to increase contrast and reduce external visual clues during behavioral recording. Trials were 
video-recorded using an SJ4000 action camera (SJCAM, Ltd., Shenzhen, China) at 60 frames/s. We assessed 
the mean distance (cm), not moving duration (s) and time spent in top (s), based on the center body position 
computation, using the EthoVision XT11.5 software (Noldus IT, Wageningen, Netherlands), as  in57,109.
The LDT was chosen here as another widely used test to study anxiety in  zebrafish49,110. The apparatus repre-
sented a 20-L acrylic tank (20 height × 50 length × 20 width cm) divided into two equal compartments (one white 
and one black) filled with water for up to 15 cm. Trials were recorded by an SJ4000 video-camera and stored for 
further off-line analyses, similar to the NTT testing. Each video was then scored offline by highly trained observ-
ers (blinded to the treatments) to assess time spent (s) in, and the number of entries to, the light (white) zone.
The ST was chosen for this study as a commonly used test to assess social and stress-related behavioral phe-
notypes in  zebrafish111, using behavioral apparatus similar to the NTT described above. During testing, the fish 
from each group were placed in the tank in groups of 5 and (following a 5-min acclimation to the apparatus) 
their shoals were photographed using an SJ4000 video-camera every 10 s, resulting in 6 photos taken per tank 
(n = 24 for weeks 1–3, n = 18 for week 4–5), similar  to111,112. Each photo was next calibrated to the size of the tank, 
and then analyzed by two highly-trained observers (blinded to the groups), measuring the average inter-fish 
distance (cm) and distance to the surface (cm) of each fish in the photo, using the ImageTool software (University 
of Texas Health Sciences Center, San Antonio, TX). The recorded NTT, LDT and ST behavioral endpoints fully 
corresponded to the established behavioral phenotypes described in the Zebrafish Behavioral Catalog (ZBC)113.
The ZTI test was applied here as a recently developed novel test for characterizing stress and drug effects 
in adult zebrafish, analogous to rodent despair-like behavioral tests, and bidirectionally sensitive to both acute 
stressors and antidepressant  treatment68. Given complex interplay between despair-like behavior and chronic 
stress in  rodents28,114–116, it was particularly interesting to assess the effects of CUS effects on zebrafish behavior 
in the ZTI test. Briefly, the caudal part of each fish was immobilized for 6 min using the wet viscose sponge (8 
length × 4 height × 5 width cm) cut in the middle with a sharp scalpel to a 2-cm depth from the bottom, and 
attached to the top of the beaker using two additional 2-cm cuts of the sponge on the sides, to allow fixation by 
the beaker walls, as described in detail  in68. The cranial part of the fish body thus remaining freely hanging verti-
cally in a small beaker (a 7 × 5.5–4.8 cm transparent plastic cup shaped as a truncated cone) filled with  water68. 
Trials were video-recorded using an SJ4000 action camera at 60 frames/s, and then scored offline by three highly 
trained observers to assess the total duration (s) of active escape attempts (defined here as continuous bouts 
of body torsion movements separated from each other by episodes of immobility—complete cessation of body 
movements, except for gills and eyes) for more than 2 s each, according  to68.
Neurochemical analyses. Brain monoamines are an important factor in stress and affective disorders 
both clinically and in rodents and zebrafish  models37,68,117–121. To study dynamic changes in their levels in 
stressed zebrafish, the whole-brain concentrations of norepinephrine (NE), serotonin (5-HT), dopamine (DA) 
and their metabolites 5-HIAA, DOPAC and homovanillic acid (HVA) were assayed using the high-performance 
liquid chromatography (HPLC), as  in68,119–121. As shown in Fig. 1, brain samples were collected one day after the 
behavioral battery, between 9:00 and 13.00 h. The 1-day interval was used here to minimize concomitant imme-
diate effects of behavioral testing and/or handling, enabling us to focus on baseline CUS-evoked neurochemi-
cal changes instead. In our pilot studies, we used behaviorally tested (n = 5 for group × week pair, i.e., exposed 
to the battery of tests) and experimentally naïve (n = 5, unexposed to behavioral testing) fish, to analyze their 
neurochemical parameters. As we found no significant effect of tested vs. naïve CUS-exposed fish as predictor 
in the Generalized Linear Model (GZLM, Supplementary Table S7), the two fish subgroups were combined for 
assessing neurochemical changes. Fish for neurochemical analyses were chosen randomly from the respective 
experimental and testing groups, using an online random number generator (www.rando m.org). Samples were 
used for further analyses without pooling.
Briefly, the fish were euthanized in ice-cold water immediately after being taken from the hometanks, and 
their brains dissected on ice and stored in liquid nitrogen for prior analyses, as  in68. On the day of analyses, all 
samples were weighted and placed into 10 μL of ice-cold 0.1-M perchloric acid (Sigma Aldrich, St. Louis, MO, 
USA) solution with 100 ng/mL 3,4-dihydroxybenzylamin (DHBA, internal standard) per 1 mg of brain tissue 
for the preservation of neurochemical analytes, similar  to68. Then samples were next sonicated for 10 s at half-
power settings, cleared by centrifugation and filtered through a 0.22-μm Durapore-PVDF centrifuge filter (Merck 
Millipore, Billerica, MA, USA), as  in68. HPLC was performed using a CA-5ODS column and with a HTEC-500 
chromatograph (Eicom, San Diego, CA, USA) with a carbon WE-3 G electrode WE-3 G using a + 650-mV applied 
potential. Chromatography mobile phase consisted of 0.1 M phosphate buffer, 400 mg/L sodium octylsulphonate, 
50 mg/L ethylenediaminetetraacetic acid (EDTA), 17—% methanol and was adjusted to pH 4.5 by phosphoric 
acid (all reagents were purchased from Sigma Aldrich, St. Louis, MO, USA), as  in68. The concentrations data 
were normalized using individual DHBA sample concentrations, and presented as pg/mg of brain tissue weight. 
We also assessed the 5-HIAA/serotonin, DOPAC/dopamine and HVA/dopamine ratios, reflecting the turnover 
of the respective monoamines in the brain, similar  to68.
RNA-sequencing. Brain samples for gene expression analyses were collected without pooling (1 brain per 
sample) one day after the last test of behavioral battery, between 9:00 and 13.00. The 1-day interval was used here 
to minimize concomitant immediate genomic effects of behavioral testing and/or handling, enabling us to focus 
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on baseline CUS-evoked changes instead. Fish (n = 6–7) for RNA-sequencing analysis were chosen randomly 
from the experimental groups using a random number generator. Similar to the neurochemical analyses, the 
fish were quickly euthanized in ice-cold water immediately after being taken from the hometanks, and their 
brains dissected on ice and stored in liquid nitrogen for further analyses. For RNA isolation, brains were fro-
zen in liquid nitrogen immediately after dissection. RNA isolation was made with TRI-reagent (MRC, Cat. no. 
118) according to manufacturer instructions. Quality was checked with Quantus, electrophoresis, and QIAxel. 
PolyA RNA was purified with Dynabeads mRNA Purification Kit (Ambion). Illumina library was made from 
polyA RNA with NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB) according to manual. 
Sequencing was performed on Illumina HiSeq2500 with 140 bp read length, with at least 27 million reads gener-
ated for each sample.
Qualitative real-time polymerase chain reaction (qRT-PCR). To reconfirm the validity of our 
RNAseq data, we also conducted a small qualitative real-time PCR study of selected genes, quantifying whole-
brain expression of four ‘reference’ genes (isg15, saga, otx5 and tpm4b) and one housekeeping gene (b-act) using 
the established qrt-PCR  protocol48,119,122,123, with minor modifications. The genes were chosen based on their 
hubness in core PPI groups and on different expression patterns between groups (isg15—differentially expressed 
in both stress and fluoxetine vs. control, saga—in stress vs. fluoxetine, otx5—stress vs. both control and fluox-
etine and tpm4b—in stress vs. control). Primers were designed using the National Center for Biotechnology 
Information (NCBI) Primer-BLAST (Basic Local Alignment Search Tool) database (https ://blast .ncbi.nlm.nih.
gov/Blast .cgi), or using primers from our past experiments (b-act) (Supplementary Table S1) and synthesized 
by Evrogen, Ltd. (Moscow, Russia). Similar to other molecular analyses here, samples for qRT-PCR were col-
lected without pooling (1 brain per sample) one day after the last test of behavioral battery, between 9:00 am 
and 1.00 pm. As already noted, the 1-day interval was used here to minimize concomitant immediate genomic 
effects of behavioral testing and/or handling, enabling us to focus on baseline CUS-evoked changes instead. 
Fish (n = 10) for analysis were chosen randomly from the experimental groups using an online random number 
generator. The fish were quickly euthanized in ice-cold water immediately after being taken from the hometanks, 
and their brains dissected on ice and stored in liquid nitrogen for further analyses. RNA isolation was made 
with TRIzol analogue ExtractRNA (Evrogen, Ltd.) according to manufacturer instructions. We next synthesized 
cDNA using oligo(dT)20 primers using similar amount of RNA per sample (MMLV RT kit by Evrogen, Ltd.). 
Finally, we performed qRT-PCR with qPCRmix-HS SYBR (Evrogen, Ltd.) using CFX Connect Real-Time sys-
tem (Bio-Rad laboratories, Hercules, CA, USA) in 3 replicates for each sample. The PCR sequences consisted of 
an initial incubation for 5 min at 95 °C to activate the Taq DNA polymerase, followed by 95 °C for 20 s (dena-
turing), 60 °C for 30 s (annealing), and 72 °C for 20 s (extension). Gene expression levels were normalized to 
the RNA expression of the housekeeping β-actin gene (relative quantification) using the Pfaffl  method124,125. All 
samples with detectable signals were included in final analyses reported here.
Statistical analyses and data handling. The present study utilized GZLMs to analyze dynamic changes 
observed following chronic unpredictable stress and fluoxetine treatment. GZLM is a generalization of regres-
sion methods that allows variables to have distributions other than a normal distribution, thus making it suitable 
for non-normal data  analyses126. GZLM are widely used in various  fields127–129, including zebrafish neurobehav-
ioral  studies130. For behavioral and neurochemical analysis, we performed the Wald chi-square (χ2) analysis 
of variance (ANOVA, Type II; Tables 2, 3) for GZLM (Supplementary Tables S1, S5), fits, followed by Tukey’s 
post-hoc testing for significant GZLM/Wald pair-wise comparison data (Figs. 2, 3, Tables 2, 3, Supplementary 
Tables S2–S4). GZLM is an effective method for analyzing multifactorial data that provides robust results both 
for nonparametric and parametric  data127,128,131,132. To assess dynamic effects on zebrafish behavior, GZLM week, 
group and their interaction effects were used as predictors comparing stress and control group at CUS weeks 
1–5 (GZLM1). To study fluoxetine treatment effects, we used another model with only 3 groups (control, stress, 
fluoxetine) at week 5 of treatment, to avoid dynamic model unsaturation (lack of weeks 1–4’s effect for fluox-
etine group), thus limiting ANOVA capabilities to assess drug effects (GZLM2). To choose optimal GZLM dis-
tribution and link functions (goodness of fit) for each endpoint, we compared (where applicable) the Akaike 
information criterion (AIC)  levels133,134 of Gaussian distribution (identity link), Poisson distribution (with log 
link), Gamma distribution (inverse and log links) and Inverse Gaussian distribution (with inverse and log links), 
choosing the least AIC score (indicating the model most likely to be correct)135. To assess potential behavioral 
battery effects on zebrafish neurochemistry, we applied a similar approach, using GZLM with week, group, their 
interaction and battery in CUS weeks 1–5 control vs. stress effects. Since no effect of behavioral battery was 
observed in any given model (p > 0.05 by GZLM, Supplementary Table S7), the test battery factor was excluded 
from further analyses, thus modeling only group, week and their interaction as predictors. To analyze week 5 
data, we used a similar GZLM approach. All calculations were performed using the R  software136.
The Goodman and Kruskal’s gamma correlation test (gamma-test) was used to study correlations between 
all mean values of endpoints observed in the groups for each week (mean values of group × week pairs). Since 
no fish was individually traced during behavioral testing and subsequent neurochemical analysis, mean values 
of endpoints observed in the groups for each week were used for the gamma test, resulting in n = 12 samples. 
Additionally, we studied neurochemical effects of behavioral battery comparing fish exposed to the battery 
(n = 5) with fish that continued to be exposed to the CUS protocol without battery exposure, using the Wilcoxon-
Mann–Whitney U-test.
The sample size was chosen here based on previously published studies on zebrafish stress-related behavior, 
including own  works48,68,120,121,123 and sample size estimation using the R package pwr2. Briefly, for GZLM1, 
the effect sizes for two factors were estimated using distance (as one of basic zebrafish endpoints)  from48 (stress 
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effect; effect size = 0.68)  and57 (day effect; effect size = 0.75). Similarly, for GZLM2, the lowest distance effect size 
 from48 among stress and fluoxetine was used (0.68). Power was chosen as 0.9 (0.1 chance of type II error), and 
alpha level was chosen as 0.05. The resulting n = 4 for GZLM1 and n = 11 for GZLM2 were further adjusted to 
account for potential mortality (e.g., due to CUS exposure), the number of individual fish samples needed for 
neuromolecular analyses, and potential presence of endpoints with smaller effect sizes. Finally, we initially started 
with n = 20 during the beginning of CUS protocol (weeks 1–3), but reduced n to 15 during weeks 4–5, in line 
with ethical principles to reduce the number of animals used in research, as no overt mortality was observed in 
the present study due to CUS. Graphs were constructed using the ggplot2 R package version 3.3.0 (https ://ggplo 
t2.tidyv erse.org)137. All fish tested were included in final analyses without attrition or exclusion, and all planned 
analyses were reported here. All experimenters were blinded to the treatment groups during behavioral testing, 
neurochemical and genomic analyses, including statistics and video analysis using individual codes for fish/
groups identification. Manual scoring of behavior was performed by two highly-trained experimenters blinded 
to the treatment (intra/inter-rater reliability > 0.85, as assessed by Spearman correlation).
To analyze differential gene expression, reads were mapped to the zebrafish GRCz11 reference genome using 
STAR spliced  aligner138 and further processed using  featureCounts139 to obtain raw gene counts. A total of 32,057 
genes were used for analyses using the R environment for statistical  computing136, Bioconductor  software140, and 
DESeq2  package141. This method was chosen as a recommended tool for experiments with 12 or fewer replicates 
per condition, stable even within 0.5-fold-change thresholds, and generally consistent with other tools, such as 
EdgeR (when using exact test), Limma and  EBSeq142. First, all rows without counts or only with a single count 
across all samples were removed from the analysis, yielding 28,932 genes. Differential expression analyses on the 
Negative Binomial (Gamma-Poisson) distribution were next performed by estimation of size factors, dispersion, 
and negative binomial generalized linear models and Wald statistics using the DESeq function. The p-values 
were adjusted using the Benjamini–Hochberg correction. p-value and false discovery rate (FDR) were set at 0.05. 
Differential expression analyses were applied to the stressed group vs. control group, fluoxetine treated group vs. 
control group and fluoxetine treated group vs. stressed group.
The resultant significantly altered genes in groups were verified for existence in other group comparisons for 
convenience, resulting in gene sets uniquely represented only in original differential expression analyses and gene 
sets shared between analyses, yielding in two sets: genes co-expressed in both stressed and fluoxetine groups vs. 
control and genes that were found to be differentially expressed in stressed group vs. control and then found to be 
differentially expressed between fluoxetine treated group vs. stressed group, thus restoring their expression levels 
to the control group levels. MA-plots (Bland–Altman plots) were constructed using the ggplot2 R  package137. 
Unless specified otherwise, all data were expressed as mean ± standard error of mean (S.E.M.), and p set as < 0.05 
in all analyses. For qRT-PCR analysis (Fig. 6), we performed Kruskal–Wallis (KW) test with post-hoc Dunn’s 
test for pairwise comparison for significant KW data (see Supplementary Table S10 for details). Analyses of all 
data in this study were performed offline without blinding the analysts to the treatments, since all animals and 
samples were included in analyses, data were analyzed in a fully unbiased automated method, and the analysts had 
no ability to influence the results of the experiments, as  in119. The study experimental design and its description 
here, as well as data analyses and presenting, adhered to the ARRIVE guidelines for reporting animal research 
and the PREPARE guidelines for planning animal research and testing.
Gene set enrichment analysis (GSEA). GSEA is widely used to study gene expression data arranged 
in known molecular pathways, allowing for a better detection of biologically relevant  changes143–146. However, 
classical GSEA has some inherent limitations, including the inability to handle datasets of different sizes and 
complex experimental  designs147. A subset of GSEA, the generally applicable gene set enrichment (GAGE) for 
the pathways analysis addressed these  limitations147, enabling to choose independent pathways databases to 
be analyzed depending on research goals, hence consistently outperforming classical GSEA  methods147. The 
KEGG and GO pathway enrichment analyses were performed on normalized and log2-transformed counts by 
the GAGE  package147, using two-sample Student’s t-test for group comparison of differential expression of gene 
sets. The FDR cut-off was set at 0.05 for the KEGG pathways and 0.01 for the GO pathways. The FDR for GO 
pathways was reduced to 0.01 since it has more pathways than KEGG (~ 40 000 vs. ~ 500) and 0.05 FDR for GO 
results in large amount of significantly altered pathways, whereas we wanted to focus on the most significant 
pathways. Sets were additionally grouped by similarity of core genes that contribute to pathways enrichment by 
function esset.grp (cutoff p-value 10e−10), to provide clear representation of their functional connection, choos-
ing the most enriched gene sets among functionally related sets when  needed148.
Topological analyses. Topological analyses were performed using the Cytoscape software for integrated 
models of biomolecular interaction networks version 3.8.0149,150. The protein–protein interaction (PPI) networks 
were constructed based on all significantly different genes from all analyses using the STRING (Search Tool 
for the Retrieval of Interacting Genes/Proteins)  database151 (https ://strin g-db.org/cgi/input .pl), with significant 
PPIs and the addition of 20 proteins suggested by STRING analyses as being closely related to the network 
(i.e., excluding text mining, and all proteins that had no connections to the main network), with the level of 
minimal required interaction score in STRING at db = 0.15. The resultant PPI networks were analyzed by the 
Cytoscape application  cytoHubba152 to probe essential nodes/hubs in-network for top 10 degree nodes, top 10 
bottleneck nodes or top 10 nodes by the Double Screening Scheme (DSS), combining Density of Maximum 
Neighborhood Component (DMNC) and Maximum Neighborhood Component (MNC)152. The degree of the 
node v was defined as the number of edges of node v, thus representing the number of a protein’s connections 
to other proteins. The bottleneck nodes were determined using the betweenness centrality of the node, based on 
the measuring of the number of shortest passes going through the  node153. Bottleneck proteins are likely to be 
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essential in the network functioning as connectors bridge-like  proteins154. MNC of the node v was defined as a 
size of the maximum connected component of subnetwork N(v) constructed by nodes adjacent to v. DMNC of 
the node v was defined as E/Nε where N is node number and E is edge number of MNC(v), and ε is defined as 1.7. 
DSS was further calculated as follows: for n most possible essential proteins that were expected in the output (n 
is an empirical value), 2n top-ranked proteins were selected by DMNC method. The resulting proteins were then 
ranked by MNC value, and top n proteins picked. DSS (DMNC||MNC) method is an effective method to identify 
essential  proteins155. The gene co-expression networks were also constructed in the same way, as PPI networks 
using the Cytoscape application  GeneMANIA156–158 (https ://genem ania.org/) for zebrafish gene co-expression 
data, and analyzed similarly to the PPI networks.
Finally, to visualize the resulting networks, we used power graph analysis (PGA)—a novel method of analysis 
and representations of complex networks, in which usual nodes and edges are replaced with power nodes and 
power edges constructed from common topological structures: ‘cliques’ (set of nodes with an edge between 
each pair, represented as a loop), ‘bicliques’ (two sets of nodes with edge between every member of other set; 
represented as two power nodes connected with power edge) and ‘stars’ (set of nodes connected to single node; 
represented as power node connected to usual node)159. PGA is an effective tool to compress information con-
tained in the network and to improve its visual representation, helping to focus on key ‘hub’  nodes159. The present 
study constructed power graphs for both STRING and GeneMANIA networks, aiming to improve the overall 
visual representation of molecular networks revealed here (Supplementary Figs. S4, S5).
Ethical confirmation statements. Animal experiments were approved by IACUC of St. Petersburg State 
University and fully adhered to the National and Institutional guidelines and regulations on animal experimen-
tation, as well as the 3Rs principles of humane animal experimentation.
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding authors 
upon reasonable requests.
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